SG Americas Securities
VIRX

SG Americas Securities’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

SG Americas Securities’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,454
Closed -$164K – 3886
2021
Q3 		$164K Buy
+20,454
New +$202K ﹤0.01% 3361
2015
Q2 		– Sell
-120
Closed -$62K – 2881
2015
Q1 		$62K Buy
+120
New +$60.5K ﹤0.01% 2336
2014
Q2 		– Sell
-70
Closed -$98K – 2736
2014
Q1 		$98K Buy
+70
New +$81.4K ﹤0.01% 2227

Other funds holding VIRX

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SG Americas Securities's VIRX Position: Q4 2021 in Review

SG Americas Securities sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2021, closing a stake of 20,454 shares — an estimated $164K sold.

SG Americas Securities first reported a position in VIRX in Q1 2014 and held it in 3 quarters. The position peaked at $164K in Q3 2021. 69 funds tracked by Wall St. Rank hold VIRX as of Q4 2021.

  • SG Americas Securities reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • SG Americas Securities sold 20,454 Viracta Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $164K.
  • SG Americas Securities first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 3 quarters.
  • SG Americas Securities's Viracta Therapeutics, Inc. Common Stock position peaked at $164K in Q3 2021.
  • 69 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2021.

Based on SG Americas Securities's 13F filing for Q4 2021, filed 7 Feb 2022.